FDG PET and PETCT have been shown to be most helpful in staging recurrent or metastatic breast cancer and in evaluating the response of locally advanced and metastatic breast cancer to treatment. Positron emission tomography PET is now an important cancer imaging tool both for diagnosis and staging as well as offering prognostic information based on response.
Since PET scans can detect more cancerous sites than CT scans alone they are often used in the initial staging and follow-up testing to see if and how the cancer is spreading.
Breast cancer staging pet scan. Results from a recent retrospective study conducted by Memorial Sloan Kettering Cancer Center investigators suggest that PETCT scanning might offer the most efficient and effective detection of newly diagnosed breast cancer that has spread to the bone. The National Comprehensive Cancer Network NCCN guidelines recommend assessment with positron emission tomography with 2-deoxy-2-fluorine-18fluoro-D-glucose integrated with computed tomography 18F-FDG PETCT in staging of breast cancer starting from the stage IIIA. Mammography ultrasound and breast MRI help accurately stage local disease extent whereas bone scan abdominal CT or MRI chest CT and FDG PETCT play a role in systemic staging.
Staging tells the doctor how big a cancer is and whether it has spread. 5038 – 5047 101002cncr24534. It usually takes between 30 and 60 minutes.
Knowing the stage helps your doctor decide which treatment you need. PET scan measure changes in the metabolic rate. Though the ability of PET to identify breast cancer depends on the tumors size and histology PETCT has an important role to play in determining tumor multiplicity and a selected group of women with dense breasts or implants.
To determine whether the cancer has spread to the lymph nodes. Many studies have pointed out the role of 18 F-FDG PETCT or 18 F-FDG PET in patients with clinical stage III or II breast cancer. Our aim is to evaluate the contribution of 18F-FDG PETCT in staging of breast cancer.
The test has only a limited ability to detect small tumors. The addition of FDG PET to CI for detection of recurrent neoplasm after primary treatment of breast cancer has proven to be a complementary imaging technique overcoming many of the limitations CI for re-staging. Normally a PET scan actually scans the whole body and is sometimes used as part of breast cancer staging to check for metastasis of cancer to other parts of the body.
Why you have it You may have a PET-CT scan if other tests suggest that your breast cancer might have spread to another part of the body but your doctors need to be sure. 18 F-FDG PETCT might advantageously replace other staging procedures such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomenpelvis. The additional metabolic information provided by FDG PET increases the accuracy of detecting recurrent or metastatic lesions 2-16.
18F-fluorodeoxyglucose positron emission tomographycomputed tomography FDG-PETCT imaging in the staging and prognosis of inflammatory breast cancer Cancer Internet 115 2009 pp. 2-4 Therefore the NCCN panel considered PET or PETCT to be optional in locally advanced disease but it is a category 2B recommendation. Previously PETCT contributed to the accurate staging from the stage IIB.
The only limitation in the diagnosis of breast cancer using PETCT scan is its poor detection rate for small breast carcinomas and non-invasive breast cancers. Although it is not appropriate for all patients with breast cancer FDG PETCT can have an important clinical effect for appropriate patients. PET scans can be useful for evaluating people after breast cancer has already been diagnosed in a number of different ways.
It can help doctors work out whether tissue is active cancer or not. Scinti scans are also frequently used. We discuss the findings locoregional or distant that can be expected in different categories of breast.
In contrast for patients with locally advanced breast cancer the use of PET or PETCT scanning has been reported by several studies to detect extra-axial nodal disease in 7 to 25 of cases and distant metastases in 10 to 21 over and above routine studies. A breast PETCT scan. The Royal College of Radiologists UK recommends staging with CT of the chest abdomen and pelvis for patients with large T4 tumours or with heavy lymph node burden N2 disease with or without bone scan and a PET-CT for suspected inflammatory breast cancer.
In conclusion 18F-FDG PETCT is not recommended for staging all patients with early breast cancer although evidence of improved regional and systemic staging supports its use in locally advanced breast cancer. These are the only current clinical indications for FDG PETCT in breast cancer and the only ones routinely reimbursed by the Centers for Medicare. When a breast cancer has been diagnosed some people have a CT scan of their chest and tummy abdomen to stage the breast cancer.
PET scans can be used to determine how much cancer is in a persons body and how far the cancer has spread which is called staging. To determine whether the cancer has spread to other parts of the body and if so where metastatic breast cancer. Baseline tumor glycolytic activity is associated with tumor biology and prognosis.
PET scans are not used to screen women for breast cancer.